Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Technology Hardware & Equipment
Near term
6-12 MONTHS
After modest sales growth in 2025, we expect 2026 to be softer, affected by FX headwinds, the prolonged US-Iran conflict and tariff-related budget delays in the US. We view this as transitory rather than structural, with demand fundamentals supported by a high share of sales to publicly funded universities and research institutions. A return of larger projects, absent in 2025 after three in 2024, could act as a near-term catalyst and is something we will be watching closely in H2 2026. The valuation remains below both its historical average and peer multiples, and as FX normalises and customer activity picks up, we see scope for a return to stronger growth and substantial margin expansion through operating leverage.
Long term
6+ YEARS
We see strong structural growth potential, supported by increasing adoption of motion capture technology. Beyond the near-term noise, we think the more interesting story is developing underneath with the upcoming Prisma Pose launch that will give Qualisys a fully integrated markerless offering, as well as OnTraq that is building an early subscription revenue base. According to MarketsandMarkets, the motion capture TAM is set to see a 15% CAGR from 2024 to 2029, driven by an expanding addressable market to new verticals in healthcare, media and sports, among others. This growth is expected to come from all components in 3D motion capture, including hardware, software and accessories. Qualisys targets sales growth of at least 15% per year over a business cycle, and an EBIT margin of at least 20%.
Project-related risk.
Political and client funding risk.
Long procurement cycles and external project delays can cause short-term fluctuations in revenue, profitability, and cash flows. Qualisys’ business is best assessed over longer periods, e.g., annual performance.
Volatility in profitability and cash flows based on currency fluctuations.
Price
Fair range high value
Fair range low value
The high end of our fair value range is based on a 2027e EV/EBIT of 13x, and the low end 10x.
Our fair value range is based on a peer group multiples valuation approach.
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB